DEM BioPharma Funding & Investors
DEM Bio is pioneering the next generation of immunotherapeutics that unleash macrophages and immune phagocytes to eliminate tumors by targeting ‘Don’t eat me’ (DEM) and ‘Eat me’ (EM) signals on cancer cells and macrophages. Founded by Longwood Fund and is supported by a syndicate of biotech investors and headquartered in Boston, MA.
dembiopharma.comTotal Amount Raised: $70,000,000
DEM BioPharma Funding Rounds
Series A
$70,000,000
Series A Investors
Longwood Fund ManagementEmerson CollectiveAstellas Venture ManagementUTokyo Innovation PlatformPfizer Venture InvestmentsAlta PartnersInsight Venture PartnersAlexandria Venture Investments
Funding info provided by Diffbot.